Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

NCT06813872 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06813872
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06813872 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania
Lead sponsor
Pfizer
Phase
Observational
Overall status
Active, not recruiting
Start date
February 24, 2025
Completion date
July 31, 2027
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory syncytial viruses